RecruitingNCT02000687
Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss
Sponsor
Rodolfo Alejandro
Enrollment
60 participants
Start Date
Dec 1, 2008
Study Type
OBSERVATIONAL
Conditions
Summary
This is a single-center, prospective, open label study in islet transplant recipients following islet graft loss.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Plain Language Summary
Simplified for easier understanding
This study is monitoring the long-term health of people who received an islet cell transplant (a procedure that places insulin-producing cells into people with type 1 diabetes) using a specific immune-suppressing drug protocol, to see how well they do over time.
**You may be eligible if...**
- You have type 1 diabetes and previously received an islet transplant at a participating institution
- You received your transplant under a specific research protocol being tracked by this study
- You are willing to be followed with regular check-ups and lab tests over many years
**You may NOT be eligible if...**
- Your islet transplant is no longer functional
- You did not receive your transplant under the specific research protocol this study is following
- You are unable or unwilling to comply with ongoing long-term monitoring requirements
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02000687
Related Trials
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068141 locations
Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes
NCT075489961 location
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
NCT0722432110 locations
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
NCT0670467216 locations
Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes
NCT0679129111 locations